Back to Search
Start Over
Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma
- Source :
- Annals of Hematology. 92:1149-1149
- Publication Year :
- 2013
- Publisher :
- Springer Science and Business Media LLC, 2013.
-
Abstract
- Dear Editor, We read with great interest the article published in Annals of Hematology on a patient with Langerhans/dendritic cell sarcoma arising from hairy cell leukemia with both lesions demonstrating almost identical karyotypes and identical clonal immunoglobulin gene rearrangements [1]. This case is very interesting in light of fresh data on BRAF V600E mutations in several different tumor types [2]. Whole exome sequencing of patients with hairy cell leukemia has revealed BRAF V600E mutation [3]. This BRAFV600E mutation has been described as a diseasedefining event [3] in hairy cell leukemia and has been implicated in the pathogenesis of hairy cell leukemia. Langerhans cell histiocytoses have also been reported to harbor the BRAFV600E mutation [4]. Histiocytoses are extremely rare diseases with variable clinical syndromes and BRAFV600E mutations have been reported in multiple histiocytoses subtypes including Erdheim–Chester disease [5]. In the light of these results, the case reported is very fascinating [1]. It may be interesting to profile the BRAFV600E status of the hairy cell leukemic clone and the histiocytic/dendritic sarcoma clone. If confirmed, this could suggest clonality and may also indicate a common origin of these diverse rare diseases. Moreover, for this particular patient this may have implications for targeted therapy. Vemurafenib, a BRAF inhibitor has been recently Food and Drug Administration approved for the therapy of BRAFV600E mutant metastatic melanoma [6]. Although hairy cell leukemia is a treatable disease with standard regimens, rare relapsed patients could still benefit from BRAF inhibitor targeted therapy and a proof of concept study has already been reported [7]. Some patients with Langerhans cell histocytoses may have an aggressive clinical course and patients with refractory disease may have few options. BRAF inhibitor-targeted therapy may be the way to kill two birds with one stone such as in this patient if BRAFV600E mutation is confirmed.
- Subjects :
- Langerhans cell
medicine.medical_treatment
Clone (cell biology)
Targeted therapy
medicine
Humans
Hairy cell leukemia
Vemurafenib
Histiocyte
B-Lymphocytes
Leukemia, Hairy Cell
Hypopharyngeal Neoplasms
business.industry
Hematology
General Medicine
medicine.disease
Pyriform Sinus
medicine.anatomical_structure
Histiocytoses
Cell Transdifferentiation
Immunology
Hairy Cell
Female
business
Langerhans Cell Sarcoma
medicine.drug
Subjects
Details
- ISSN :
- 14320584 and 09395555
- Volume :
- 92
- Database :
- OpenAIRE
- Journal :
- Annals of Hematology
- Accession number :
- edsair.doi.dedup.....c21e7a3414d2ef1c81989456ff167c3f